Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers—Novartis's Alcon division, Johnson & Johnson and Valeant's Bausch + Lomb unit—decided to set minimum prices for prescription contacts. Reuters reports that the committee will determine if the minimum prices harm consumers.

The newswire notes that setting a minimum price has been legal since a 2007 Supreme Court ruling said such a move is OK, but antitrust experts tell Reuters that manufacturers may have set minimums as a way to prompt optometrists to write prescriptions for their brand.

Novartis tells Reuters it decided to go with a minimum retail price to keep patients from pumping doctors for product information only to purchase contacts online at lower prices.

You must be a registered member of MMM to post a comment.

Next Article in Channel


Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.